Top

Published in:

01-08-2017 | Review Article

PIM1: a promising target in patients with triple-negative breast cancer

Authors: Wen Zhao, RuiYue Qiu, Pan Li, Jin Yang

Published in: Medical Oncology | Issue 8/2017

Abstract

Triple-negative breast cancers (TNBCs) have poor prognosis, and chemotherapy remains the mainstay of therapy because of lack of discovered possible target. MYC were found overexpressed in TNBCs compared with other subtypes and especially in those resistant to chemotherapy, but the inhibition has been challenging to achieve. Recently, the cooperation of PIM1 and MYC was identified involved in cell proliferation, migration and apoptosis of TNBCs, which has been reported in hematological malignancy and prostatic cancer. Inhibition of PIM1 can promote the apoptosis of tumor cells and enhance sensitivity to chemotherapy. Notably, PIM1-null mice develop normally and are fertile, suggesting the side effects can be tolerated. Thus, PIM1 may be a promising target in TNBCs and further investigation, both in vivo and in vitro, needs to be carried out.

DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–62. doi:10.3322/caac.21203.CrossRefPubMed

Newman LA, Reis-Filho JS, Morrow M, Carey LA, King TA. The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: triple-negative breast cancer. Ann Surg Oncol. 2015;22(3):874–82. doi:10.1245/s10434-014-4279-0.CrossRefPubMed

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429–34. doi:10.1158/1078-0432.ccr-06-3045.CrossRefPubMed

Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. Lancet (Lond, Engl). 2012;379(9814):432–44. doi:10.1016/s0140-6736(11)61625-5.CrossRef

Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet (Lond, Engl). 2014;384(9938):164–72. doi:10.1016/s0140-6736(13)62422-8.CrossRef

Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, et al. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014;4(2):232–45. doi:10.1158/2159-8290.cd-13-0286.CrossRefPubMed

Wang J, Kim J, Roh M, Franco OE, Hayward SW, Wills ML, et al. Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene. 2010;29(17):2477–87. doi:10.1038/onc.2010.10.CrossRefPubMedPubMedCentral

Keeton EK, McEachern K, Dillman KS, Palakurthi S, Cao Y, Grondine MR, et al. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood. 2014;123(6):905–13. doi:10.1182/blood-2013-04-495366.CrossRefPubMedPubMedCentral

Braso-Maristany F, Filosto S, Catchpole S, Marlow R, Quist J, Francesch-Domenech E, et al. PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nat Med. 2016;22(11):1303–13. doi:10.1038/nm.4198.CrossRefPubMed

10.

Horiuchi D, Camarda R, Zhou AY, Yau C, Momcilovic O, Balakrishnan S, et al. PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression. Nat Med. 2016;22(11):1321–9. doi:10.1038/nm.4213.CrossRefPubMedPubMedCentral

11.

Eilers M, Eisenman RN. Myc’s broad reach. Genes Dev. 2008;22(20):2755–66. doi:10.1101/gad.1712408.CrossRefPubMedPubMedCentral

12.

Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J, et al. Genomic targets of the human c-Myc protein. Genes Dev. 2003;17(9):1115–29. doi:10.1101/gad.1067003.CrossRefPubMedPubMedCentral

13.

Dang CV. c-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol Cell Biol. 1999;19(1):1–11.CrossRefPubMedPubMedCentral

14.

Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008;8(12):976–90. doi:10.1038/nrc2231.CrossRefPubMed

15.

Rahl PB, Lin CY, Seila AC, Flynn RA, McCuine S, Burge CB, et al. c-Myc regulates transcriptional pause release. Cell. 2010;141(3):432–45. doi:10.1016/j.cell.2010.03.030.CrossRefPubMedPubMedCentral

16.

Jain AN, Chin K, Borresen-Dale AL, Erikstein BK, Eynstein Lonning P, Kaaresen R, et al. Quantitative analysis of chromosomal CGH in human breast tumors associates copy number abnormalities with p53 status and patient survival. Proc Natl Acad Sci USA. 2001;98(14):7952–7. doi:10.1073/pnas.151241198.CrossRefPubMedPubMedCentral

17.

Horiuchi D, Kusdra L, Huskey NE, Chandriani S, Lenburg ME, Gonzalez-Angulo AM, et al. MYC pathway activation in triple-negative breast cancer is synthetic lethal with CDK inhibition. J Exp Med. 2012;209(4):679–96. doi:10.1084/jem.20111512.CrossRefPubMedPubMedCentral

18.

Chandriani S, Frengen E, Cowling VH, Pendergrass SA, Perou CM, Whitfield ML, et al. A core MYC gene expression signature is prominent in basal-like breast cancer but only partially overlaps the core serum response. PLoS ONE. 2009;4(8):e6693. doi:10.1371/journal.pone.0006693.CrossRefPubMedPubMedCentral

19.

Alles MC, Gardiner-Garden M, Nott DJ, Wang Y, Foekens JA, Sutherland RL, et al. Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the “basal” breast cancer subgroup. PLoS ONE. 2009;4(3):e4710. doi:10.1371/journal.pone.0004710.CrossRefPubMedPubMedCentral

20.

Gatza ML, Lucas JE, Barry WT, Kim JW, Wang Q, Crawford MD, et al. A pathway-based classification of human breast cancer. Proc Natl Acad Sci USA. 2010;107(15):6994–9. doi:10.1073/pnas.0912708107.CrossRefPubMedPubMedCentral

21.

Wong DJ, Liu H, Ridky TW, Cassarino D, Segal E, Chang HY. Module map of stem cell genes guides creation of epithelial cancer stem cells. Cell Stem Cell. 2008;2(4):333–44. doi:10.1016/j.stem.2008.02.009.CrossRefPubMedPubMedCentral

22.

Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A, et al. An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet. 2008;40(5):499–507. doi:10.1038/ng.127.CrossRefPubMedPubMedCentral

23.

Chang DW, Claassen GF, Hann SR, Cole MD. The c-Myc transactivation domain is a direct modulator of apoptotic versus proliferative signals. Mol Cell Biol. 2000;20(12):4309–19.CrossRefPubMedPubMedCentral

24.

Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000;14(19):2501–14.CrossRefPubMedPubMedCentral

25.

Seo HR, Kim J, Bae S, Soh JW, Lee YS. Cdk5-mediated phosphorylation of c-Myc on Ser-62 is essential in transcriptional activation of cyclin B1 by cyclin G1. J Biol Chem. 2008;283(23):15601–10. doi:10.1074/jbc.M800987200.CrossRefPubMedPubMedCentral

26.

Prochownik EV, Vogt PK. Therapeutic targeting of Myc. Genes Cancer. 2010;1(6):650–9. doi:10.1177/1947601910377494.CrossRefPubMedPubMedCentral

27.

Cuypers HT, Selten G, Quint W, Zijlstra M, Maandag ER, Boelens W, et al. Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell. 1984;37(1):141–50.CrossRefPubMed

28.

van Lohuizen M, Verbeek S, Krimpenfort P, Domen J, Saris C, Radaszkiewicz T, et al. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell. 1989;56(4):673–82.CrossRefPubMed

29.

Narlik-Grassow M, Blanco-Aparicio C, Carnero A. The PIM family of serine/threonine kinases in cancer. Med Res Rev. 2014;34(1):136–59. doi:10.1002/med.21284.CrossRefPubMed

30.

Brault L, Gasser C, Bracher F, Huber K, Knapp S, Schwaller J. PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica. 2010;95(6):1004–15. doi:10.3324/haematol.2009.017079.CrossRefPubMedPubMedCentral

31.

Saris CJ, Domen J, Berns A. The pim-1 oncogene encodes two related protein-serine/threonine kinases by alternative initiation at AUG and CUG. EMBO J. 1991;10(3):655–64.PubMedPubMedCentral

32.

Bergamaschi A, Kim YH, Wang P, Sorlie T, Hernandez-Boussard T, Lonning PE, et al. Distinct patterns of DNA copy number alteration are associated with different clinicopathological features and gene-expression subtypes of breast cancer. Genes Chromosom Cancer. 2006;45(11):1033–40. doi:10.1002/gcc.20366.CrossRefPubMed

33.

Andre F, Job B, Dessen P, Tordai A, Michiels S, Liedtke C, et al. Molecular characterization of breast cancer with high-resolution oligonucleotide comparative genomic hybridization array. Clin Cancer Res. 2009;15(2):441–51. doi:10.1158/1078-0432.ccr-08-1791.CrossRefPubMed

34.

Turner N, Lambros MB, Horlings HM, Pearson A, Sharpe R, Natrajan R, et al. Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene. 2010;29(14):2013–23. doi:10.1038/onc.2009.489.CrossRefPubMedPubMedCentral

35.

Bazarov AV, Hines WC, Mukhopadhyay R, Beliveau A, Melodyev S, Zaslavsky Y, et al. Telomerase activation by c-Myc in human mammary epithelial cells requires additional genomic changes. Cell Cycle (Georgetown, TX). 2009;8(20):3373–8. doi:10.4161/cc.8.20.9856.CrossRef

36.

Zippo A, De Robertis A, Serafini R, Oliviero S. PIM1-dependent phosphorylation of histone H3 at serine 10 is required for MYC-dependent transcriptional activation and oncogenic transformation. Nat Cell Biol. 2007;9(8):932–44. doi:10.1038/ncb1618.CrossRefPubMed

37.

Fox CJ, Hammerman PS, Cinalli RM, Master SR, Chodosh LA, Thompson CB. The serine/threonine kinase Pim-2 is a transcriptionally regulated apoptotic inhibitor. Genes Dev. 2003;17(15):1841–54. doi:10.1101/gad.1105003.CrossRefPubMedPubMedCentral

38.

Yan B, Zemskova M, Holder S, Chin V, Kraft A, Koskinen PJ, et al. The PIM-2 kinase phosphorylates BAD on serine 112 and reverses BAD-induced cell death. J Biol Chem. 2003;278(46):45358–67. doi:10.1074/jbc.M307933200.CrossRefPubMed

39.

Dautry F, Weil D, Yu J, Dautry-Varsat A. Regulation of pim and myb mRNA accumulation by interleukin 2 and interleukin 3 in murine hematopoietic cell lines. J Biol Chem. 1988;263(33):17615–20.PubMed

40.

Mochizuki T, Kitanaka C, Noguchi K, Muramatsu T, Asai A, Kuchino Y. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem. 1999;274(26):18659–66.CrossRefPubMed

41.

Bachmann M, Kosan C, Xing PX, Montenarh M, Hoffmann I, Moroy T. The oncogenic serine/threonine kinase Pim-1 directly phosphorylates and activates the G2/M specific phosphatase Cdc25C. Int J Biochem Cell Biol. 2006;38(3):430–43. doi:10.1016/j.biocel.2005.10.010.CrossRefPubMed

42.

Wang Z, Bhattacharya N, Mixter PF, Wei W, Sedivy J, Magnuson NS. Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochem Biophys Acta. 2002;1593(1):45–55.CrossRefPubMed

43.

Morishita D, Katayama R, Sekimizu K, Tsuruo T, Fujita N. Pim kinases promote cell cycle progression by phosphorylating and down-regulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res. 2008;68(13):5076–85. doi:10.1158/0008-5472.can-08-0634.CrossRefPubMed

44.

Zhang Y, Wang Z, Magnuson NS. Pim-1 kinase-dependent phosphorylation of p21Cip1/WAF1 regulates its stability and cellular localization in H1299 cells. Mol Cancer Res. 2007;5(9):909–22. doi:10.1158/1541-7786.mcr-06-0388.CrossRefPubMed

45.

Aho TL, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett. 2004;571(1–3):43–9. doi:10.1016/j.febslet.2004.06.050.CrossRefPubMed

46.

Chao DT, Linette GP, Boise LH, White LS, Thompson CB, Korsmeyer SJ. Bcl-XL and Bcl-2 repress a common pathway of cell death. J Exp Med. 1995;182(3):821–8.CrossRefPubMed

47.

Bachmann M, Moroy T. The serine/threonine kinase Pim-1. Int J Biochem Cell Biol. 2005;37(4):726–30. doi:10.1016/j.biocel.2004.11.005.CrossRefPubMed

48.

Amaravadi R, Thompson CB. The survival kinases Akt and Pim as potential pharmacological targets. J Clin Investig. 2005;115(10):2618–24. doi:10.1172/jci26273.CrossRefPubMedPubMedCentral

49.

Wang Z, Bhattacharya N, Weaver M, Petersen K, Meyer M, Gapter L, et al. Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J Vet Sci. 2001;2(3):167–79.PubMed

50.

White E. The pims and outs of survival signaling: role for the Pim-2 protein kinase in the suppression of apoptosis by cytokines. Genes Dev. 2003;17(15):1813–6. doi:10.1101/gad.1123103.CrossRefPubMed

51.

Yip-Schneider MT, Horie M, Broxmeyer HE. Transcriptional induction of pim-1 protein kinase gene expression by interferon gamma and posttranscriptional effects on costimulation with steel factor. Blood. 1995;85(12):3494–502.PubMed

52.

Matikainen S, Sareneva T, Ronni T, Lehtonen A, Koskinen PJ, Julkunen I. Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood. 1999;93(6):1980–91.PubMed

53.

Nawijn MC, Alendar A, Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat Rev Cancer. 2011;11(1):23–34. doi:10.1038/nrc2986.CrossRefPubMed

54.

Mikkers H, Nawijn M, Allen J, Brouwers C, Verhoeven E, Jonkers J, et al. Mice deficient for all PIM kinases display reduced body size and impaired responses to hematopoietic growth factors. Mol Cell Biol. 2004;24(13):6104–15. doi:10.1128/mcb.24.13.6104-6115.2004.CrossRefPubMedPubMedCentral

55.

Block KM, Hanke NT, Maine EA, Baker AF. IL-6 stimulates STAT3 and Pim-1 kinase in pancreatic cancer cell lines. Pancreas. 2012;41(5):773–81. doi:10.1097/MPA.0b013e31823cdd10.PubMedPubMedCentral

56.

Mizuno K, Shirogane T, Shinohara A, Iwamatsu A, Hibi M, Hirano T. Regulation of Pim-1 by Hsp90. Biochem Biophys Res Commun. 2001;281(3):663–9. doi:10.1006/bbrc.2001.4405.CrossRefPubMed

57.

Shay KP, Wang Z, Xing PX, McKenzie IF, Magnuson NS. Pim-1 kinase stability is regulated by heat shock proteins and the ubiquitin-proteasome pathway. Mol Cancer Res. 2005;3(3):170–81. doi:10.1158/1541-7786.mcr-04-0192.CrossRefPubMed

58.

Malinen M, Jaaskelainen T, Pelkonen M, Heikkinen S, Vaisanen S, Kosma VM, et al. Proto-oncogene PIM-1 is a novel estrogen receptor target associating with high grade breast tumors. Mol Cell Endocrinol. 2013;365(2):270–6. doi:10.1016/j.mce.2012.10.028.CrossRefPubMed

59.

Laird PW, van der Lugt NM, Clarke A, Domen J, Linders K, McWhir J, et al. In vivo analysis of Pim-1 deficiency. Nucleic Acids Res. 1993;21(20):4750–5.CrossRefPubMedPubMedCentral

60.

Abadi AH, Abouel-Ella DA, Lehmann J, Tinsley HN, Gary BD, Piazza GA, et al. Discovery of colon tumor cell growth inhibitory agents through a combinatorial approach. Eur J Med Chem. 2010;45(1):90–7. doi:10.1016/j.ejmech.2009.09.029.CrossRefPubMed

61.

Magnuson NS, Wang Z, Ding G, Reeves R. Why target PIM1 for cancer diagnosis and treatment? Future Oncol. 2010;6(9):1461–78. doi:10.2217/fon.10.106.CrossRefPubMedPubMedCentral

Title: PIM1: a promising target in patients with triple-negative breast cancer
Authors: Wen Zhao
RuiYue Qiu
Pan Li
Jin Yang
Publication date: 01-08-2017
Publisher: Springer US
Published in: Medical Oncology / Issue 8/2017
Print ISSN: 1357-0560
Electronic ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-017-0998-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

PIM1: a promising target in patients with triple-negative breast cancer

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2017

Clinical and prognosis value of the CIMP status combined with MLH1 or p16 INK4a methylation in colorectal cancer

Post-trimodality expression levels of metadherin (MTDH) as a prognostic biomarker for esophageal adenocarcinoma patients

Impact of venous invasion on the efficacy of adjuvant chemotherapy in elderly patients with stage III colorectal cancer

Predictors of the usefulness of duloxetine for chemotherapy-induced peripheral neuropathy

Identification of a novel leukemic-specific splice variant of DNMT3B and its stability

Local and systemic immunity predict survival in patients with pulmonary sarcomatoid carcinoma

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page